Hannah Valantine net worth and biography

Hannah Valantine Biography and Net Worth

Director of CareDx

Hannah Valantine received her M.B.B.S. degree from London University, cardiology fellowship at Stanford, and Doctor of Medicine from London University. She was appointed Assistant Professor of Medicine, rising to full Professor of Medicine in 2000, and becoming the inaugural Senior Associate Dean for Diversity and Leadership, in 2004. She pursued a data-driven transformative approach to this work, receiving the NIH director’s pathfinder award. Dr. Francis Collins, NIH director, recruited her in 2014 as the inaugural NIH Chief Officer for Scientific Workforce diversity, and as a tenured investigator in the National Heart, Lung, and Blood Institute’s intramural research program where she established the laboratory of transplantation genomics. Dr. Valantine is a nationally recognized pioneer in her field, with over 200 peer-reviewed publications, patents, and sustained NIH funding. She was elected to the National Academy of Medicine in 2020 for both her pioneering research in organ transplantation and workforce diversity.

What is Hannah Valantine's net worth?: The estimated net worth of Hannah Valantine is at least $144.90 thousand as of November 12th, 2025. Dr. Valantine owns 7,465 shares of CareDx stock worth more than $144,896 as of December 5th. This net worth estimate does not reflect any other assets that Dr. Valantine may own. Learn More about Hannah Valantine's net worth.
How do I contact Hannah Valantine?: The corporate mailing address for Dr. Valantine and other CareDx executives is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. CareDx can also be reached via phone at (415) 287-2300 and via email at [email protected]. Learn More on Hannah Valantine's contact information.
Has Hannah Valantine been buying or selling shares of CareDx?: Hannah Valantine has not been actively trading shares of CareDx during the last ninety days. Most recently, Hannah Valantine sold 10,570 shares of the business's stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $19.16, for a transaction totalling $202,521.20. Following the completion of the sale, the director now directly owns 38,994 shares of the company's stock, valued at $747,125.04. Learn More on Hannah Valantine's trading history.
Who are CareDx's active insiders?: CareDx's insider roster includes Paul Adler (CEO), George Bickerstaff, III (Director), Christine Cournoyer (Director), Ankur Dhingra (CFO), Michael Goldberg (Director), William Hagstrom (Director), Abhishek Jain (CFO), Sasha King (CMO), Peter Maag (Insider), Reginald Seeto (Insider), Ralph Snyderman (Director), Thomas Thomas (Director), and Hannah Valantine (Director). Learn More on CareDx's active insiders.
Are insiders buying or selling shares of CareDx?: In the last twelve months, insiders at the sold shares 9 times. They sold a total of 139,343 shares worth more than $2,424,611.09. The most recent insider tranaction occured on July, 7th when Director Peter Maag sold 10,000 shares worth more than $185,800.00. Insiders at CareDx own 4.4% of the company. Learn More about insider trades at CareDx.
Information on this page was last updated on 7/7/2025.

Hannah Valantine Insider Trading History at CareDx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/18/2025	Sell	10,570	$19.16	$202,521.20	38,994

Hannah Valantine Buying and Selling Activity at CareDx

CareDx Company Overview

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Today's Range

Now: $19.41

$18.63

$19.80

50 Day Range

MA: $15.67

$14.28

$19.41

2 Week Range

Now: $19.41

$10.96

$26.24

Volume

1,081,385 shs

Average Volume

872,948 shs

Market Capitalization

$998.26 million

P/E Ratio

16.31

Dividend Yield

N/A

Beta

2.54